Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results deaths Eclinical improvement Edeath or ventilation E

COVID-19 severe or critically meta-analysis

REMAP-CAP (tocilizumab)
 
NCT02735707
RCTtocilizumab standard of careCOVID-19 severe or criticallysome concern
353/402 conclusif -27% demonstrated58%
Rosas (REMDACTA)
 
NCT04409262
RCTtocilizumab placeboCOVID-19 severe or criticallysome concern
434/215 inconclusive -5% -2%
Talaschian
 
IRCT20081027001411N4
RCTtocilizumab standard of careCOVID-19 severe or criticallysome concern
20/20 inconclusive 23%
Veiga
 
NCT04403685
RCTtocilizumab standard of careCOVID-19 severe or criticallysome concern
65/64 safety concern safety concern153% 49%
CORIMUNO-TOCI-1 (Group 1)
 
NCT04331808
RCTtocilizumab standard of careCOVID-19 severe or criticallysome concern
64/67 inconclusive -7% -39%
CORIMUNO-TOCI-ICU (Group 2)
 
NCT04331808
RCTtocilizumab standard of careCOVID-19 severe or criticallysome concern
49/43 inconclusive -32%
COVACTA (Rosas)
 
NCT04320615
RCTtocilizumab placeboCOVID-19 severe or criticallysome concern
301/151 suggested 25% 17%
8 studies excluded by filtering options (2 RCT / 6 OBS)

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).